Clinical Journal of the American Society of Nephrology · 19 Nov 2026
Mechanisms for Behavior Change and Adherence to Treatment for Comorbid Depression in CKD
Meredith C. McAdamsh-index 6, Genna F. Hymowitz, Giselle A. Gerardi, Lynnel C. Goodman, L. Parker Gregg, Xiaoyue Zhang, Thomas Carmody, Amelia Dubovsky, Madhukar H. Trivedih-index 113, Rajnish Mehrotra, S. Susan Hedayatih-index 42
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background: Major depressive disorder (MDD) disproportionately affects people with chronic kidney disease (CKD) and is associated with non-adherence. We evaluated facilitators of and barriers to adherence to treatments for MDD among people with CKD. Methods: The CONCORD randomized controlled trial evaluated two treatment strategies vs. control for MDD in people with CKD G3b-5: Behavioral Activation Therapy (BAT) (plus placebo) or antidepressant bupropion (plus clinical management control) administered for 8 weeks, with escalation to a combination of BAT plus bupropion for another 8 weeks in those without MDD remission. The control arm received placebo and clinical management. BAT and clinical management were administered via video-teleconferencing. Focus groups were held virtually among study completers and one-on-one interviews among non-completers. The blinded allocation was kept concealed. An applied thematic analysis approach was used for data analysis using NVivo 15. Results: Fourteen focus groups (total N=52) and seven one-on-one interviews were conducted. The cohort was 58% women, 29% Black persons, and 31% Hispanic persons. Median (IQR) age was 59 (51, 64) years and mean (SD) estimated glomerular filtration rate was 27 (9) mL/min/1.73 m 2 . Adherence to study capsule by pill count was higher among focus group vs. one-on-one participants, but adherence to video-teleconferencing sessions was similar. Barriers to drug adherence included polypharmacy, large pill size, side effects attributed to study capsule, and forgetting to take medication. Facilitators of adherence included expectation of symptom improvement and desire to help others by knowledge gained. Participants reported a positive impact of participation on overall functioning and symptoms and indicated that skills learned in teletherapy were helpful. Some perceived video-teleconferencing sessions as more effective than medication, others attributed benefit to a combination of medication and video-teleconferencing, and a minority perceived medication as most effective. Conclusion: Facilitators of and barriers to treatment adherence can inform the management of MDD in people with CKD.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Madhukar H. Trivedi has the highest h-index among the authors (113).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.